0.75Open0.75Pre Close0 Volume226 Open Interest2.50Strike Price0.00Turnover0.00%IV-3.55%PremiumJul 19, 2024Expiry Date0.81Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.33Leverage Ratio--Theta--Rho--Eff Leverage--Vega
ProQR Therapeutics Stock Discussion
NEWS
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipelin...
1. $Viking Therapeutics(VKTX.US)$ closest competitor to $Madrigal Pharmaceuticals(MDGL.US)$ , which recently announced breakthroughs in the NASH space and price went up ×4 times. multiple catalysts in 2023 q1.
2. $ProQR Therapeutics(PRQR.US)$ announced collaboration with LLY, their RNAI editing softwa...
$AMC Entertainment(AMC.US)$ $AppTech Payments(APCX.US)$ $Core Scientific(CORZ.US)$ $iMedia Brands(IMBI.US)$ $CarMax(KMX.US)$ $Mersana Therapeutics(MRSN.US)$ $NVIDIA(NVDA.US)$ $Oric Pharmaceuticals(ORIC.US)$ $ProQR Therapeutics(PRQR.US)$ $Rocket Pharmaceuticals(RCKT.US)$ $Roku Inc(ROKU.US)$ $Cassava Sciences(SAVA.US)$ $Tesla(TSLA.US)$ $Expion360(XPON.US)$
No comment yet